Leerink Partnrs Predicts Gilead Sciences Q1 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Gilead Sciences in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of $1.98 for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.35 per share. Leerink Partnrs also issued estimates for Gilead Sciences’ Q2 2025 earnings at $2.02 EPS, Q3 2025 earnings at $2.03 EPS, FY2025 earnings at $7.79 EPS, FY2026 earnings at $9.08 EPS, FY2027 earnings at $9.97 EPS, FY2028 earnings at $10.21 EPS and FY2029 earnings at $10.48 EPS.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%.

Several other equities analysts also recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday. Truist Financial raised their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Wolfe Research began coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Oppenheimer increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.33.

Gilead Sciences Trading Up 7.5 %

Shares of Gilead Sciences stock opened at $103.31 on Thursday. The company has a 50-day moving average of $93.38 and a two-hundred day moving average of $87.24. The stock has a market cap of $128.75 billion, a PE ratio of 1,147.89, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $104.71.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.06%. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock valued at $53,611,715 over the last quarter. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of GILD. Bellevue Group AG lifted its position in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after purchasing an additional 7,093 shares in the last quarter. Quantinno Capital Management LP lifted its stake in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC boosted its holdings in Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares during the last quarter. IRON Financial LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $830,000. Finally, Capital Investment Advisors LLC increased its holdings in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after purchasing an additional 9,791 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.